COMMUNIQUÉS West-GlobeNewswire

ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
21/01/2026
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, [...]
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
21/01/2026
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management [...]
NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts
21/01/2026
BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and [...]
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
21/01/2026
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE [...]
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
21/01/2026
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19 th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral [...]
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
21/01/2026
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical [...]
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
21/01/2026
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 adults and parents [...]
Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)
21/01/2026
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society [...]
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
21/01/2026
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. 21, 2026 (GLOBE [...]
InnovAge to Announce Fiscal Second Quarter 2026 Financial Results and Host Conference Call Tuesday, February 3, 2026
21/01/2026
DENVER, Jan. 21, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
21/01/2026
Interim analyses on track for the first and second half of 2026 SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused [...]
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
21/01/2026
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal [...]
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
21/01/2026
Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the [...]
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
21/01/2026
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a [...]
Skye Bioscience to Present Poster at Keystone Obesity Conference
21/01/2026
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health [...]
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
21/01/2026
Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA ® while at Regeneron Most recently served as Chief Marketing Officer, Global [...]
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
21/01/2026
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent [...]
AnswersNow Completes $40M Series B to Expand BCBA-Driven, AI-Enabled Autism Therapy
21/01/2026
RICHMOND, Va., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AnswersNow , the leader in virtual Applied Behavioral Analysis (ABA) therapy, today announced that it has raised $40 million in Series B funding led by HealthQuest [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
21/01/2026
Company Announcement Net sales of DARZALEX ® in 2025 totaled USD 14,351 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, [...]

Pages